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Abstract
Background: Major depressive disorder is a common condition that often includes cognitive dysfunction. A  systematic 
literature review of studies and a network meta-analysis were carried out to assess the relative effect of antidepressants on 
cognitive dysfunction in major depressive disorder.
Methods: MEDLINE, Embase, Cochrane, CDSR, and PsychINFO databases; clinical trial registries; and relevant conference 
abstracts were searched for randomized controlled trials assessing the effects of antidepressants/placebo on cognition. 
A network meta-analysis comparing antidepressants was conducted using a random effects model.
Results: The database search retrieved 11 337 citations, of which 72 randomized controlled trials from 103 publications met the inclusion 
criteria. The review identified 86 cognitive tests assessing the effect of antidepressants on cognitive functioning. However, the Digit 
Symbol Substitution Test, which targets multiple domains of cognition and is recognized as being sensitive to change, was the only 
test that was used across 12 of the included randomized controlled trials and that allowed the construction of a stable network suitable 
for the network meta-analysis. The interventions assessed included selective serotonin reuptake inhibitors, serotonin-norepinephrine 
reuptake inhibitors, and other non-selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors. The network 
meta-analysis using the Digit Symbol Substitution Test showed that vortioxetine was the only antidepressant that improved cognitive 
dysfunction on the Digit Symbol Substitution Test vs placebo {standardized mean difference: 0.325 (95% CI = 0.120; 0.529, P = .009}. 
Compared with other antidepressants, vortioxetine was statistically more efficacious on the Digit Symbol Substitution Test vs 
escitalopram, nortriptyline, and the selective serotonin reuptake inhibitor and tricyclic antidepressant classes.
Conclusions: This study highlighted the large variability in measures used to assess cognitive functioning. The findings on 
the Digit Symbol Substitution Test indicate differential effects of various antidepressants on improving cognitive function in 
patients with major depressive disorder.
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Major depressive disorder (MDD) is one of the most common 
psychiatric disorders, affecting more than 350 million people 
worldwide (World Health Organization, 2016). MDD is character-
ized by psychological, physical, and behavioral symptoms that 
can be complex and vary widely between individuals. In general, 
patients with MDD experience a prolonged period of low mood 
often accompanied by low self-esteem, loss of interest in usually 
enjoyable activities, feelings of hopelessness, and low energy 
(World Health Organization, 2016). MDD exerts a substantial 
burden on the patient, including a negative impact on health-
related quality of life (Daly et  al., 2010; Fournier et  al., 2013), 
impairments in multiple domains of cognitive function, prema-
ture mortality due to a range of physical disorders, and suicide 
in about 4% to 15% of patients (Seguin et al., 2006; Gonda et al., 
2007; American Psychiatric Association, 2013). As of 2010, the 
World Health Organization has listed MDD as the second lead-
ing cause of disability worldwide, and it is expected to become 
the leading cause of disease burden in high-income countries by 
2030 (Mathers and Loncar, 2006; Ferrari et al., 2013).
Patients with MDD often experience impairment in cognitive 
function in several domains, including executive functioning, 
processing speed, concentration/attention, learning, and mem-
ory (Porter et al., 2007; Hammar and Ardal, 2009; Baune et al., 
2010; Beblo et al., 2011; National Academies of Sciences, 2015). 
Patients with MDD may experience cognitive impairments 
not only before and during depressive episodes but also after 
remission of mood symptoms (Baune et  al., 2010; Papakostas 
and Culpepper, 2015). A 3-year prospective study of 267 patients 
found that cognitive problems were present 94% of the time 
during depressive episodes and 44% of the time during remis-
sion (Conradi et al., 2011). In addition to the burden for patients, 
cognitive dysfunction in mood disorders including depression is 
also associated with economic and psychosocial consequences 
(Baune et al., 2010, 2013; Baune and Malhi, 2015). These impair-
ments may lead to debilitating problems for patients such as 
missed workdays, poor academic performance, and a reduced 
ability to carry out day-to-day tasks (McIntyre et  al., 2015). 
This, in turn, can lead to elevated costs due to absenteeism 
and reduced productivity, which are the main drivers of the 
economic burden due to MDD (Marazziti et al., 2010; National 
Academies of Sciences, 2015). Cognitive dysfunction is increas-
ingly becoming recognized as an important symptom dimen-
sion of MDD. The Diagnostic and Statistical Manual 5 lists 
impairment in cognition (i.e., diminished ability to think or con-
centrate, or indecisiveness) as a diagnostic criterion for MDD 
(American Psychiatric Association, 2013). In addition, cognitive 
dysfunction has recently been identified by the Food and Drug 
Administration as a target for pharmacological treatments in 
patients with MDD (Food and Drug Administration, 2016).
Many clinical studies of antidepressants have shown 
improvements in cognition; however, there are several 
unanswered questions, including whether certain classes of 
antidepressants are superior to others in improving neuro-
psychological function. Studies suggest that serotonin nor-
epinephrine reuptake inhibitors (SSRIs), including duloxetine 
and other antidepressants such as vortioxetine, bupropion, and 
moclobemide, may improve cognitive function in depression 
(Baune and Renger, 2014). Vortioxetine, a novel antidepressant 
with multimodal activity, has shown evidence of cognitive bene-
fit in animal models (Wallace et al., 2014; Sanchez et al., 2015) as 
well as in patients with MDD (Katona et al., 2012; McIntyre et al., 
2014; Mahableshwarkar et al., 2015). Clinical effect of vortioxe-
tine on cognitive function is reported in the product characteris-
tics in many countries, including in Europe. In addition, a recent 
meta-analysis by McIntyre et al. included 3 randomized con-
trolled trials (RCTs) and showed that vortioxetine significantly 
improved cognition measured by the Digit Symbol Substitution 
Test (DSST), independent of changes in overall depressive symp-
toms (McIntyre et al., 2016).
Numerous studies have investigated cognitive function 
in depression in a variety of cognitive domains, including 
attention, processing speed, executive function, and mem-
ory. Nevertheless, there is limited evidence on the compara-
tive effectiveness of antidepressants on cognitive symptoms, 
mainly due to the diversity of tools used in clinical trials cre-
ating heterogeneous outcomes. At least 3 recent reviews were 
conducted to investigate the effects of antidepressants on cog-
nitive dysfunction (Baune and Renger, 2014; Keefe et al., 2014; 
Rosenblat et al., 2016). These reviews highlighted the fact that 
antidepressants may reduce cognitive dysfunction in MDD. 
However, the variability in the study design and the high level 
of heterogeneity of cognitive tests are important limitations 
in assessing the relative effect of antidepressants on cognitive 
dysfunction in MDD.
Objectives
The objective of this study was to assess the comparative effect 
of a variety of antidepressants on cognitive dysfunction, as 
measured by DSST, in patients with MDD through a system-
atic literature review and a network meta-analysis (NMA). The 
DSST is the most extensively used and validated cognitive test 
in neuropsychology (Jaeger and Zaragoza Domingo, 2016). The 
current analysis presents the results of the comparison of vari-
ous classes and single antidepressants vs placebo on improving 
cognitive dysfunction as assessed on the DSST.
Significance Statement
Cognitive dysfunction is a common impairment for patients with major depressive disorder (MDD) and leads to debilitating 
problems such as missed workdays, poor academic performance, and reduced ability to perform day-to-day tasks. Numerous 
studies have investigated cognitive function in depression in a variety of domains, including attention, processing speed, execu-
tive function, and memory. Nevertheless, there is limited evidence on comparative effectiveness of antidepressants on cognitive 
symptoms, mainly due to the diversity of tools used in clinical trials. This study compared the effects of antidepressants on a 
commonly used cognitive outcome, the Digit Symbol Substitution Test (DSST), and showed that vortioxetine had the largest 
improvement in DSST vs all investigated classes of single antidepressants. It was the only antidepressant demonstrating stat-
istically significant improvement vs placebo and vs specific antidepressants. The findings support the effect of vortioxetine in 
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A systematic literature review (SLR) was carried out to appraise 
the clinical evidence currently available, focusing on RCTs for 
interventions treating cognitive dysfunction in adult patients 
with MDD. Studies were obtained from a comprehensive search 
of Embase, MEDLINE, MEDLINE In-Process, Cochrane Central 
Register of Controlled Trials (CENTRAL), Cochrane Database 
for Systematic Reviews (CDSR), and PsychINFO, from database 
inception date to 13 November 2014. Hand-searching of con-
ference abstracts and trial registries (American Psychiatric 
Association, International College of Neuropsychology, European 
College of Neuropsychopharmacology, International College of 
Neuropsychopharmacology, Clinical.trials.gov, and European 
Union Clinical Trials Register) was also conducted to retrieve 
clinical studies that are unpublished in journals as full-text arti-
cles or supplement results of previously published studies.
To be included in this review, trials had to meet the prede-
fined eligibility criteria provided in Table 1. The review focused 
on evidence from RCTs assessing the impact of antidepressants 
or placebo on cognitive dysfunction in adult patients with MDD, 
with no restrictions on gender, race, or publication language. 
Studies that evaluated the effect of the interventions included 
in Table 1 were eligible for inclusion.
A first-pass screening of each citation was conducted based 
on the abstracts. Citations that did not match the eligibility cri-
teria and duplicates (due to overlap in the coverage of the data-
bases) were excluded at the first-pass stage. Full-text copies of 
all included references were then assessed, and citations that 
did not match the eligibility criteria were excluded at the sec-
ond-pass screening.
During data extraction, publications describing the same 
trial were compiled into a single entry to avoid double counting 
of patients and studies. Data were extracted on methodological 
and clinical characteristics of the studies, including sample size, 
age, gender, race, disease duration, disease severity, interven-
tions assessed, study duration, and assessment time points. 
Both stages of screening and the data extraction were carried 
out by 2 independent reviewers, and any discrepancies between 
reviewers were reconciled by a third independent reviewer.
Studies were critically appraised using comprehensive 
assessment criteria based on the recommendations in the NICE 
guidelines (NICE, 2013) according to 7 categories: (1) statistical 
analyses, (2) outcome selection and reporting, (3) withdrawals, 
(4) blinding, (5) baseline comparability, (6) allocation conceal-
ment, and (7) randomization.
Table 1. Eligibility Criteria for Trials to Be Included in the SLR
Parameter Inclusion/exclusion criteria in current review
Patient population • Age: adult patients (≥18 years of age)
• Gender: any
• Race: any
• Disease: major depressive disorder
Study design • RCTs (irrespective of blinding status)
• Comparative controlled trials (including nonrandomized studies, retrospective and prospective 
controlled cohort studies) will be included during screening stage to supplement the RCTs in case of 
limited evidence
Intervention Pharmacological interventions
• SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, 
sertraline)
• SNRIs (desvenlafaxine, duloxetine, venlafaxine, milnacipran, levomilnacipran)
• TCAs (desipramine, imipramine, clomipramine, nortriptyline, tianeptine, 
dothiepin, opipramol, trimipramine, lofepramine, dibenzepin, amitriptyline, 
protriptyline, doxepin, melitracen, butriptyline, dimetacrine, quinupramine)
• TeCA (mirtazapine, maprotiline, mianserin, amoxapine)
• MAOI (moclobemide, isocarboxazid, tranylcypromine, phenelzine, toloxatone)
Nonpharmacological interventions





















Effect on cognition and 
cognitive impact 
assessment
• Studies evaluating the effect of above listed interventions on cognition in MDD patients were included
• Studies that assess the impact of cognitive dysfunction on patient’s daily functioning, work productivity, 
and quality of life were also of interest in the review
Comparator • Any of the above included interventions
• Placebo/best supportive care
• Any other pharmacological/nonpharmacological therapy
Publication timeframe • From database inception till 13 November 2014
Language • English language articles
Abbreviations: MAOI, monoamine oxidase inhibitor; RCT, randomized controlled trial; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin 
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Evidence Network Development
A feasibility assessment was carried out to determine possible 
approaches for developing an NMA to compare the compara-
tive effect of antidepressants on cognitive dysfunction. Two 
approaches were considered: (1) Assessing studies evaluating 
the same cognitive test, irrespective of cognitive domain; and (2) 
assessing studies evaluating the same cognitive domain, irre-
spective of the test. The second approach was not pursued due 
to the lack of consensus for categorizing cognitive symptoms 
into cognitive domains. In addition, considering the large variety 
of 86 cognitive tests used as endpoints in the reviewed studies, 
collapsing these into domain-specific groups would introduce 
a validity bias, since different cognitive tests measure differ-
ent cognitive abilities, even within the same cognitive domain. 
Moreover, because certain individual tests would qualify to be 
assigned to different cognitive domains, this would introduce 
uncertainty when interpreting the results. To overcome several 
of these problems and allow for the generation of a stable NMA, 
the first approach evaluating studies with a common cognitive 
test was chosen for the NMA.
Across the 72 included RCTs, 86 different cognitive tests were 
used to assess the effect of antidepressants on cognitive dys-
function in patients with MDD. Most of the tests were used in 
only one study. A total of 12 tests were reported in 4 or more 
studies, with the Mini-Mental State Examination (MMSE) and 
DSST being the most commonly reported outcomes (13 stud-
ies each). Even across studies that evaluated cognitive function 
using the same test, there were variations in reporting outputs. 
For example, some studies reported the mean score as an end-
point, while others reported either the percentage of correct 
answers or a time estimate. Additionally, some studies reported 
different and/or multiple domains for the same test, and there 
was variation in whether the cognitive endpoint was a primary 
or secondary outcome. The MMSE is considered to be a poor 
choice to measure cognitive function in MDD, because it broadly 
measures global cognitive function, has no alternate form, and 
has extreme ceiling effects (Keefe et al., 2014). In addition, the 
MMSE is most commonly used for evaluating cognition in late-
life depression due to evidence of its validity for dementia (Rajji 
et al., 2009). Furthermore, the MMSE did not allow for a compari-
son of all antidepressant drug classes. Other tests were also not 
appropriate for the network in our analyses: Stroop, Trail Making 
Test A (TMT A) and Trail Making Test B (TMT B), and Rey Auditory 
Verbal Learning Test (RAVLT) were each reported in only 8 to 9 
trials, and their networks were all smaller than the DSST net-
work. The networks of these 4 tests decomposed into 2, 4, 3, 
and 4 subnetworks for Stroop, TMT A and TMT B, and RAVLT, 
respectively. Since these networks decomposed into small sub-
networks, only a limited comparison of 1 to 3 (depending on the 
subnetwork) other antidepressants vs placebo, duloxetine, and 
vortioxetine was possible. In contrast, for the DSST, it was pos-
sible to construct a single “connected” network that allowed for 
multiple comparisons across various antidepressants as shown 
in the Results. As a conclusion, the subsequent analyses and 
results are presented for the NMA using published clinical trials 
that utilized the DSST.
The DSST is a “pencil and paper” cognitive test that assesses 
several aspects of the cognitive function that are most impaired 
in patients with MDD, such as components of executive func-
tion, processing speed, attention, and working memory. It is rec-
ognized as being sensitive to change during effective treatment 
of MDD (Jaeger and Zaragoza Domingo, 2016; McIntyre et  al., 
2016). The DSST is sensitive to both the presence of cognitive 
dysfunction and the change in cognitive function across a wide 
range of clinical populations. Due to its brief administration 
time and high discriminant (known group) validity, the DSST is 
a frequently used test that allows the opportunity to benchmark 
clinical effects. DSST performance is one of the most robust pre-
dictors of outcomes in patients with severe illness and has been 
shown to correlate with functional outcomes.
NMA
To simultaneously assess the comparative effects of more 
than 2 treatments, an NMA was performed. An NMA synthe-
sizes direct and indirect comparisons over an entire network 
of treatments, allowing for all available evidence to be con-
sidered in one analysis. Based on the network development 
process as outlined above, the outcome variable for the NMA 
was the standardized mean change in the DSST (measured 
using Hedge’s G) from baseline to end of study. The stand-
ardization was based on the pooled (across treatment arms 
within study) estimate of the SDs. The NMA was carried out 
using a frequentist’s approach, and a 2-way ANOVA model was 
used. As the residual variances between treatment groups are 
known, it was possible for random effect estimates to be pro-
duced, which account for the between-trial heterogeneity. The 
model was first used to perform ordinary pairwise meta-anal-
ysis comparing the antidepressants to placebo based on direct 
evidence from the clinical studies. Secondly, for the NMA, 
2 networks were developed: one network by drug class and 
another by type of antidepressant. Ranking probabilities were 
calculated based on the joint distribution of the estimates of 
relative efficacy.
Consistency was addressed through the principle of node-
splitting by using a network meta-regression model. The pur-
pose of node-splitting is to investigate if the relative effect of 
2 treatments based on direct comparisons is comparable with 
the same effect based on indirect comparisons. Statistically, the 
model is an extension of the NMA, which allows for a different 
relative effect between the 2 treatments that are being split in 
head-to-head trials compared with all other trials.
Results
SLR
Figure  1 shows the flow of studies through the systematic 
review process. Searching of literature databases yielded 11 337 
references. Due to the overlap of coverage between the data-
bases, 1676 abstracts were found to be duplicates and were 
removed. First-stage screening of the citations identified 1425 
potentially relevant references based on their titles/abstracts. 
Full-text reports of these citations were obtained for more 
detailed evaluation, following which 190 references remained. 
Hand-searching identified 20 additional relevant citations, 
resulting in a total of 210 publications prior to extraction.
The review focused on RCTs assessing pharmacological 
interventions, as RCTs are considered the gold standard of clini-
cal evidence and they minimize the risk of confounding factors. 
Of the 210 references screened, 72 RCTs from 103 publications 
were identified based on prespecified eligibility criteria and 
included for data extraction.
The interventions assessed across the studies included 
SSRIs (citalopram, escitalopram, fluoxetine, paroxetine, sertra-
line, or fluvoxamine), serotonin and norepinephrine reuptake 
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levomilnacipran), monoamine oxidase inhibitors (phenelzine 
or tranylcypromine), tricyclic antidepressants (desipramine, 
amitriptyline, imipramine, trimipramine, or tianeptine), tetra-
cyclic antidepressants (mianserin or mirtazapine), or non-SSRI/
SNRI antidepressants (agomelatine, bupropion, reboxetine, or 
vortioxetine).
DSST As the Single Cognitive Measure for Network 
Development
Although there was large variation in the cognitive meas-
ures used in the RCTs, the DSST was the only cognitive end-
point from the reviewed studies that could be used as a test 
Figure 1. Flow diagram for the identification and selection of studies. Note: 12 studies that assessed Digit Symbol Substitution Test (DSST) were included in the final 
























Figure 2. Network for the (a) by-class analysis and (b) by-treatment analysis. Note: The size (area) of the nodes is proportional to the number of patients on treatment. 
The width of the lines is proportional to the number of patients in trials with direct comparison between the nodes. The numbers on the lines indicate the number of 
trials with direct comparisons, if it is more than one. Abbreviations: MOAI, monoamine-oxidase inhibitor; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, 
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of cognitive dysfunction for developing a homogeneous and 
“stable” network of evidence to compare various antidepres-
sants (see Methods). One study was excluded in the absence of 
a common link with the other antidepressants, resulting in 12 
studies (3738 patients) in the final network (Tignol et al., 1998). 
DSST was the primary endpoint in 2 of the trials included in the 
network, and these both assessed vortioxetine (McIntyre et al., 
2014; Mahableshwarkar et al., 2015); all other studies in the net-
work assessed DSST as a secondary outcome.
The total number of patients in the RCTs where the DSST was 
employed as a primary or secondary cognitive endpoint ranged 
from 27 to 602, the mean age ranged from 36.6 to 79.6 years, and 
the percentage of males ranged from 24% to 58%. The time of 
DSST assessment in the studies included in the network varied 
from 3 to 24 weeks after baseline assessment. The antidepres-
sants assessed (with analyzable number of patients in brack-
ets) were SNRIs (duloxetine [707 patients]), SSRIs (citalopram [84 
patients], escitalopram [54 patients], fluoxetine [127 patients], 
sertraline [240 patients]), MAOIs (phenelzine [28 patients]), tri-
cyclic antidepressants (TCAs) (desipramine [9 patients], nor-
triptyline [102 patients]), and non-SSRI/SNRIs (vortioxetine [725 
patients]). Vortioxetine and duloxetine have the most subjects 
in which cognition was assessed by the DSST in clinical trials. 
The majority (9 of 12) of the studies included a placebo control. 
The studies included in the DSST network of evidence and their 
characteristics are presented in Supplementary Table S1.
Critical appraisal of the included studies was conducted 
using comprehensive assessment criteria based on the recom-
mendations in the NICE guidelines (NICE, 2013). The studies 
were generally of good quality with around 4 of the 7 categories 
being assessed as low risk on average. The best scoring category 
was the baseline comparability (83% low risk) and the worst 
scoring category was outcome selection and reporting (25% low 
risk). The FOCUS trial was the best quality, with all 7 aspects of 
the assessment deemed to be low risk (McIntyre et al., 2014). 
However, the overall risk of bias was unclear in the majority of 
the categories for 5 of the 12 studies. A summary of the qualita-
tive assessment is provided in Supplementary Table S2.
As a result, 2 networks for the studies using the DSST were 
developed: one network by drug class and another by type of 
antidepressant. The network diagrams in Figure  2 provide a 
graphical representation of how each intervention is connected 
to the others through direct comparisons. Each line depicts a 
direct comparison between 2 intervention nodes. A forest plot 
showing the standardized mean differences for each study 
in direct comparisons, based on data reported in each of the 
included studies, is shown in Figure 3.
NMA
Figure  4 shows the standardized mean differences on DSST 
comparing antidepressant classes as well as individual antide-
pressants vs placebo. In the by-class analysis (Figure 4a), SSRIs, 
MAOIs, and TCAs showed a smaller effect on DSST vs placebo, 
with TCAs showing a significantly worse effect on DSST than 
placebo. Vortioxetine and SNRIs were the only antidepressant 
classes showing an improvement in DSST vs placebo, and this 
difference was statistically significant in the comparison of vor-
tioxetine vs placebo.
When comparing individual antidepressants vs placebo, 
vortioxetine, duloxetine and sertraline showed an improve-
ment in the DSST vs placebo, with vortioxetine being the 
only antidepressant showing a statistically significant dif-
ference. The standardized mean difference on the change in 
the DSST from baseline for vortioxetine vs placebo was 0.325 
[95% CI = 0.120; 0.529, P = .009]. The differences for duloxetine 
and sertraline vs placebo were not statistically significant. 
All other antidepressants (citalopram, desipramine, escit-
alopram, fluoxetine, nortriptyline, and phenelzine) demon-
strated a smaller effect on cognitive dysfunction vs placebo 
(Figure 4b).
Table 2 shows the comparative effects between antidepres-
sants in terms of standardized mean differences in the DSST 
for both the treatment class analysis (upper triangle) and the 
individual treatment analysis (lower triangle). The order of the 
treatments in the diagonal is based on the efficacy of the treat-
ment classes as well as the individual antidepressants. The 2 
most efficacious antidepressants in terms of improvement in 
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Figure  3. Standardized mean differences in Digit Symbol Substitution Test 
(DSST) of antidepressants based on direct evidence from clinical studies 
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of cognitive dysfunction for developing a homogeneous and 
“stable” network of evidence to compare various antidepres-
sants (see Methods). One study was excluded in the absence of 
a common link with the other antidepressants, resulting in 12 
studies (3738 patients) in the final network (Tignol et al., 1998). 
DSST was the primary endpoint in 2 of the trials included in the 
network, and these both assessed vortioxetine (McIntyre et al., 
2014; Mahableshwarkar et al., 2015); all other studies in the net-
work assessed DSST as a secondary outcome.
The total number of patients in the RCTs where the DSST was 
employed as a primary or secondary cognitive endpoint ranged 
from 27 to 602, the mean age ranged from 36.6 to 79.6 years, and 
the percentage of males ranged from 24% to 58%. The time of 
DSST assessment in the studies included in the network varied 
from 3 to 24 weeks after baseline assessment. The antidepres-
sants assessed (with analyzable number of patients in brack-
ets) were SNRIs (duloxetine [707 patients]), SSRIs (citalopram [84 
patients], escitalopram [54 patients], fluoxetine [127 patients], 
sertraline [240 patients]), MAOIs (phenelzine [28 patients]), tri-
cyclic antidepressants (TCAs) (desipramine [9 patients], nor-
triptyline [102 patients]), and non-SSRI/SNRIs (vortioxetine [725 
patients]). Vortioxetine and duloxetine have the most subjects 
in which cognition was assessed by the DSST in clinical trials. 
The majority (9 of 12) of the studies included a placebo control. 
The studies included in the DSST network of evidence and their 
characteristics are presented in Supplementary Table S1.
Critical appraisal of the included studies was conducted 
using comprehensive assessment criteria based on the recom-
mendations in the NICE guidelines (NICE, 2013). The studies 
were generally of good quality with around 4 of the 7 categories 
being assessed as low risk on average. The best scoring category 
was the baseline comparability (83% low risk) and the worst 
scoring category was outcome selection and reporting (25% low 
risk). The FOCUS trial was the best quality, with all 7 aspects of 
the assessment deemed to be low risk (McIntyre et al., 2014). 
However, the overall risk of bias was unclear in the majority of 
the categories for 5 of the 12 studies. A summary of the qualita-
tive assessment is provided in Supplementary Table S2.
As a result, 2 networks for the studies using the DSST were 
developed: one network by drug class and another by type of 
antidepressant. The network diagrams in Figure  2 provide a 
graphical representation of how each intervention is connected 
to the others through direct comparisons. Each line depicts a 
direct comparison between 2 intervention nodes. A forest plot 
showing the standardized mean differences for each study 
in direct comparisons, based on data reported in each of the 
included studies, is shown in Figure 3.
NMA
Figure  4 shows the standardized mean differences on DSST 
comparing antidepressant classes as well as individual antide-
pressants vs placebo. In the by-class analysis (Figure 4a), SSRIs, 
MAOIs, and TCAs showed a smaller effect on DSST vs placebo, 
with TCAs showing a significantly worse effect on DSST than 
placebo. Vortioxetine and SNRIs were the only antidepressant 
classes showing an improvement in DSST vs placebo, and this 
difference was statistically significant in the comparison of vor-
tioxetine vs placebo.
When comparing individual antidepressants vs placebo, 
vortioxetine, duloxetine and sertraline showed an improve-
ment in the DSST vs placebo, with vortioxetine being the 
only antidepressant showing a statistically significant dif-
ference. The standardized mean difference on the change in 
not statistically significantly different from placebo. Placebo 
was the third most efficacious, highlighting the fact that many 
of the antidepressants have less impact on cognitive function 
vs placebo.
The analysis showed that vortioxetine was numerically more 
efficacious in terms of change in DSST from baseline than all 
other antidepressants included in the analysis. The difference 
in DSST was statistically significant for vortioxetine vs SSRIs 
and TCAs with standardized mean differences of 0.423 [95% 
CI = 0.147; 0.698, P = .006] and 0.722 [95% CI = 0.316; 1.129, P = .002], 
respectively. In the by-treatment analysis, vortioxetine was stat-
istically significantly better than escitalopram and nortriptyline 
with standardized mean differences of 0.579 [95% CI = 0.117; 
1.041, P = .021] and 0.691 [95% CI = 0.165; 1.217, P = .017], respect-
ively. Moreover, based on the by-class ranking analysis, the 
probability of vortioxetine having a higher change in DSST from 
baseline than all other classes of antidepressants (including pla-
cebo) is 97%.
Consistency was addressed by node-splitting. Due to the size 
of the network, the risk of inconsistency was relatively small, 
and only 2 potential loops were identified in each of the by-treat-
ment and by-class analyses. Although there were mild incon-
sistencies in the vortioxetine/SNRI and the placebo/SSRI/TCA 
comparisons, none were considered significant. Heterogeneity 
was mainly driven by the vortioxetine/placebo comparison. This 
was accounted for by using a random effects model for estimat-
ing both relative mean differences and their CIs in the NMA.
Discussion
Cognitive dysfunction is a well-known impairment associ-
ated with MDD and causes a significant additional burden to 
patients and society. The effects of antidepressants on cogni-
tive function are still not fully understood, but cognitive dys-
function has recently been identified by the FDA as a target 
for pharmacological treatments in patients with MDD and is 
increasingly becoming of clinical importance.
In the current review, 72 RCTs assessing cognitive function 
using 86 different cognitive measures in MDD were identified. 
Of these 72 RCTs and 68 cognitive measures, 12 studies were 
included in the network of evidence for evaluating the effect 
of antidepressants. A single measure of cognitive function, the 
DSST, was used for the NMA based on results of the network 
development process. The findings of the NMA showed that vor-
tioxetine, duloxetine, sertraline, and the SNRI class  improved 
cognitive function measured with the DSST vs placebo, with 
vortioxetine being the only antidepressant or non-SSRI/SNRI 
showing a statistically significant effect vs placebo. All other 
antidepressants or classes of antidepressants included in the 
analysis demonstrated no effect on the DSST. The comparative 
analysis showed that vortioxetine was statistically significantly 
more efficacious in terms of change in the DSST from baseline 
compared with escitalopram and nortriptyline. Placebo was the 
third most efficacious, further highlighting the fact that many of 
the antidepressants have less impact on the DSST than placebo.
These findings confirm previous research by showing that 
some antidepressants improve cognitive function, and it also 
highlights that many antidepressants and classes of antide-
pressants may have less impact on cognition than placebo 
(Baune and Renger, 2014; Keefe et al., 2014; McIntyre et al., 2016; 
Rosenblat et al., 2016). Vortioxetine showed the largest improve-
ment on the DSST, which is in line with the results of previous 
studies (McIntyre et  al., 2016; Rosenblat et  al., 2016). In addi-
tion, the current analysis showed that vortioxetine was the 
only antidepressant that demonstrated a statistically significant 
improvement on the DSST vs placebo. The European Medicines 
Agency has also recognized vortioxetine’s improvement on 
the DSST, stating that it has a statistically significant effect vs 
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Figure 4. Standardized mean difference vs placebo (a) by-class analysis and (b) by-treatment analysis. Abbreviations: CIT, citalopram; DES, desipramine; DUL, dulox-
etine; ESC, escitalopram; FLU, fluoxetine; MOAI, monoamine-oxidase inhibitor; NOR, nortriptyline; PHE, phenelzine; SER, sertraline; SNRI, serotonin and norepinephrine 
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The magnitude of the cognitive deficit in MDD is typic-
ally between 0.2 and 0.7 standardized mean differences below 
what would be normal, depending on disease state and cogni-
tive domain (Rund et al., 2006; Lee et al., 2012; Rock et al., 2014). 
For comparison, cognitive dysfunction in disorders such as 
Alzheimer’s dementia is greater than in MDD and usually up 
to several SDs greater than what would be considered normal 
(Buchanan et al., 2011). A meta-analysis of 22 studies in patients 
with MDD showed that patients were impaired on the DSST 
with a standardized mean difference of 0.55 compared with 
healthy controls. The DSST was shown to be strongly associated 
with the level of functioning at work, school, and home. These 
findings suggest that the DSST provides an effective means to 
detect clinically relevant treatment effects of antidepressants 
on important components of cognitive function in patients with 
MDD (Jaeger and Zaragoza Domingo, 2016).
Vortioxetine’s statistically significant improvement on the 
DSST is likely to be due to its unique pharmacological pro-
file vs other antidepressants. These mechanisms include 
increased glutamate neurotransmission (via inhibition of 
gamma-aminobutyric acid interneurons expressing 5-HT3 
heteroreceptors) and neuroplasticity in brain regions such as 
hippocampus and prefrontal cortex (Haddjeri et al., 2012; Riga et 
al., 2013; Sanchez et al., 2015; Pehrson et al., 2015). For example, 
vortioxetine significantly enhances excitatory synaptic trans-
mission and neuroplasticity (increased cell proliferation and 
maturation) compared with SSRIs (Dale et al., 2014). In addition, 
cognitive improvements with vortioxetine may be due to direct 
and/or indirect effects via serotonergic, noradrenergic, choliner-
gic, dopaminergic, and histaminergic systems (Elmaadawi et al., 
2015; Sanchez et al., 2015). Further research is needed to under-
stand if pharmacological differences translate into differential 
effects on cognition.
To the best of our knowledge, the current NMA included the 
largest network of evidence published to date in assessing the 
impact of antidepressants on cognitive function in MDD and 
significantly extends a recently published meta-analysis that 
included only 3 RCTs (McIntyre et al., 2016). Importantly, none 
of the previous publications have quantitatively assessed the 
comparative effects of antidepressant classes, and therefore this 
analysis provides new insights into the effects of the classes as 
well as the individual antidepressants. The strengths of our ana-
lysis include a robust and thorough SLR obtaining high-quality 
RCTs for inclusion in the analysis and consideration of hetero-
geneity within the NMA by using random effects models. In 
addition, the important issue of consistency between direct and 
indirect effects in the network was also addressed. Although the 
SLR was initially carried out in November 2014, an additional 
search was carried out in October 2016, which found no new 
studies assessing the effects on cognition using the DSST.
There are also some limitations of the current analysis. The 
evidence retrieved from the SLR suggests that there is ample 
clinical data evaluating the effect of antidepressants on cog-
nitive functioning. However, due to the lack of defined clinical 
recommendations for the management of cognitive dysfunction 
in patients with MDD, a high variability is observed in report-
ing of cognitive outcomes. There are also several methodologi-
cal constraints in the studies with regards to large variability 
in the outcomes, domains, time points of assessments, report-
ing of outputs, and patient numbers. These variations limit the 
generalizability of the results and caution the interpretation. In 
particular, vortioxetine and duloxetine had the most patients 
included in the trials in the network (725 and 707, respec-
tively), whereas the other antidepressants had between 9 and 
240 patients. Although a lower number of patients treated with 
a specific compound does not in itself bias the relative effect 
of that compound, it will decrease the likelihood of finding a 
significant difference between that compound and any of the 
other compounds, because fewer patients means wider CIs in 
the results of the NMA. It should also be noted that vortioxetine 
is very clearly significantly better than placebo, due to the rela-
tively large number of patients in trials with both vortioxetine 
and placebo. One of the reasons for vortioxetine showing a sig-
nificant difference vs other antidepressants (despite the rela-
tively few patients in the trials of the other antidepressants) is 
the generally poor performance of the SSRIs and TCAs. In addi-
tion, the DSST was only a primary endpoint in 2 of the trials, and 
3 of the studies did not include a placebo control arm.
Across the 72 RCTs identified in our review, 86 differ-
ent cognitive tests were employed and hence 2 possible 
approaches for the NMA were considered: assessing studies 
that used a common cognitive test or a common cognitive 
domain. It was decided that the network of evidence would 
be developed using the DSST as a common single cognitive 
test to reduce the amount of variability between studies as 
much as possible. The feasibility of the alternative approach, 
using a common cognitive domain, was investigated but was 
not pursued due to the lack of standardization for classifying 
the different symptoms into commonly accepted domains. It 
was also considered whether multiple tests could be included 
in the network; however, it was not considered prudent to do 
so, because different tests measure different aspects of cogni-
tive function and may span across various cognitive domains. 
In addition, the studies that could have been included would 
all sit as “appendices” to the network, and there would be 
no change to the estimates of the already included studies. 
Further, the additions would each be connected to the net-
work only through one trial, which yields very wide CIs, and 
hence it was not deemed reasonable to introduce more than 
one test in the NMA in this paper. As a consequence, our 
results have to be interpreted as an effect on the DSST only, 
and results should not be generalized to other cognitive tests 
during interpretation.
An important limitation of the underlying RCTs is the large 
variability of the reported cognitive outcomes. Although there 
is an abundance of studies exploring the effects of antidepres-
sants on cognition, the heterogeneity of cognitive tests and 
outcomes used limits the analysis that can be performed in a 
meta-analysis such as ours. The advantage of selecting the DSST 
as a single cognitive test for the NMA is that like-for-like com-
parisons between treatments could be made and that a “stable” 
network was generated for the DSST; however, the selection of 
the DSST also means that a smaller number of RCTs was used 
in the analysis. Further research using other cognitive scales is 
needed in the future, and recommendations for using a stand-
ardized cognitive test battery would be highly useful for future 
clinical research and would help to overcome some of the limi-
tations of this type of research. In addition, further research into 
the effects within different subpopulations, for example based 
on age and gender, would be valuable.
In summary, although some antidepressants have shown 
improvements in cognitive function in patients with MDD, the 
majority of antidepressants have not shown an effect on cog-
nition. Comparing the effects of a large group of antidepres-
sants across classes on single cognitive measures, the DSST 
indicated that vortioxetine was the only antidepressant that 
exerted statistically significant effects on the DSST between 
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all other antidepressants analyzed. Further research is needed 
to overcome the limitations associated with the large amount 
of heterogeneity of cognitive measures in MDD, and future 
analyses would benefit from a standardized cognitive test bat-
tery in MDD.
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